tradingkey.logo

BioCardia Inc

BCDA
1.270USD
-0.010-0.78%
Close 12/19, 16:00ETQuotes delayed by 15 min
13.47MMarket Cap
LossP/E TTM

BioCardia Inc

1.270
-0.010-0.78%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of BioCardia Inc

Currency: USD Updated: 2025-12-19

Key Insights

BioCardia Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 177/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.50.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

BioCardia Inc's Score

Industry at a Glance

Industry Ranking
177 / 404
Overall Ranking
316 / 4582
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 2 analysts
Buy
Current Rating
15.500
Target Price
+983.92%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

BioCardia Inc Highlights

StrengthsRisks
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
Growing
The company is in a growing phase, with the latest annual income totaling USD 58.00K.
Fairly Valued
The company’s latest PE is -0.90, at a medium 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 96.50K shares of this stock.

Financial Health

Currency: USD Updated: 2025-12-19

The current financial score of BioCardia Inc is 6.59, ranking 247/404 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score
6.59
Change
0

Financials

10.00

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

6.88

Operational Efficiency

2.69

Growth Potential

6.36

Shareholder Returns

7.03

BioCardia Inc's Company Valuation

Currency: USD Updated: 2025-12-19

The current valuation score of BioCardia Inc is 8.68, ranking 28/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.90, which is -54.64% below the recent high of -0.41 and -379.09% above the recent low of -4.30.

Score

Industry at a Glance

Previous score
8.68
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 177/404
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2025-12-19

The current earnings forecast score of BioCardia Inc is 8.00, ranking 168/404 in the Biotechnology & Medical Research industry. The average price target for BioCardia Inc is 15.50, with a high of 25.00 and a low of 6.00.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts
Buy
Current Rating
15.500
Target Price
+983.92%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

534
Total
6
Median
6
Average
Company name
Ratings
Analysts
BioCardia Inc
BCDA
2
CRISPR Therapeutics AG
CRSP
30
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-12-19

The current price momentum score of BioCardia Inc is 3.46, ranking 373/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.44 and the support level at 1.16, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
3.50
Change
-0.04

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.037
Sell
RSI(14)
40.404
Neutral
STOCH(KDJ)(9,3,3)
19.477
Neutral
ATR(14)
0.095
Low Volatility
CCI(14)
-133.659
Sell
Williams %R
82.143
Oversold
TRIX(12,20)
0.008
Sell
StochRSI(14)
14.381
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
1.280
Sell
MA10
1.367
Sell
MA20
1.387
Sell
MA50
1.372
Sell
MA100
1.557
Sell
MA200
1.926
Sell

Institutional Confidence

Currency: USD Updated: 2025-12-19

The current institutional shareholding score of BioCardia Inc is 3.00, ranking 197/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 3.11%, representing a quarter-over-quarter decrease of 17.06%. The largest institutional shareholder is The Vanguard, holding a total of 96.50K shares, representing 0.91% of shares outstanding, with 230.29% increase in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Lincoln Alternative Strategies LLC
800.00K
--
Satterfield (Thomas A Jr)
336.00K
-13.44%
Blank (Andrew Scott)
144.54K
--
Altman (Peter)
218.60K
+28.14%
CM Management, LLC
130.00K
+73.33%
Allen (Jim L)
109.66K
-0.00%
The Vanguard Group, Inc.
Star Investors
12.88K
--
Frost Gamma Investments Trust
85.76K
-18.12%
Stertzer (Simon H)
118.69K
+49.48%
Mcclung (David)
47.95K
+11.17%
1
2

Risk Assessment

Currency: USD Updated: 2025-12-19

The current risk assessment score of BioCardia Inc is 1.77, ranking 302/404 in the Biotechnology & Medical Research industry. The company's beta value is 0.57. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
1.77
Change
0
Beta vs S&P 500 index
0.57
VaR
+8.70%
240-Day Maximum Drawdown
+64.65%
240-Day Volatility
+100.03%

Return

Best Daily Return
60 days
+12.69%
120 days
+27.03%
5 years
+168.19%
Worst Daily Return
60 days
-10.34%
120 days
-23.78%
5 years
-44.70%
Sharpe Ratio
60 days
-0.61
120 days
-0.58
5 years
-0.17

Risk Assessment

Maximum Drawdown
240 days
+64.65%
3 years
+97.40%
5 years
+98.52%
Return-to-Drawdown Ratio
240 days
-0.73
3 years
-0.33
5 years
-0.20
Skewness
240 days
+0.79
3 years
+9.23
5 years
+9.42

Volatility

Realised Volatility
240 days
+100.03%
5 years
+122.16%
Standardised True Range
240 days
+13.16%
5 years
+117.22%
Downside Risk-Adjusted Return
120 days
-75.60%
240 days
-75.60%
Maximum Daily Upside Volatility
60 days
+52.45%
Maximum Daily Downside Volatility
60 days
+44.15%

Liquidity

Average Turnover Rate
60 days
+6.29%
120 days
+4.08%
5 years
--
Turnover Deviation
20 days
-67.71%
60 days
-83.61%
120 days
-89.36%

Peer Comparison

Biotechnology & Medical Research
BioCardia Inc
BioCardia Inc
BCDA
5.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
Amicus Therapeutics Inc
FOLD
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
Krystal Biotech Inc
KRYS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
Charles River Laboratories International Inc
CRL
8.41 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals Inc
MDGL
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQVIA Holdings Inc
IQV
8.30 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more

FAQs

How does TradingKey generate the Stock Score of BioCardia Inc?

The TradingKey Stock Score provides a comprehensive assessment of BioCardia Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of BioCardia Inc’s performance and outlook.

How do we generate the financial health score of BioCardia Inc?

To generate the financial health score of BioCardia Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects BioCardia Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of BioCardia Inc.

How do we generate the company valuation score of BioCardia Inc?

To generate the company valuation score of BioCardia Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare BioCardia Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of BioCardia Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of BioCardia Inc.

How do we generate the earnings forecast score of BioCardia Inc?

To calculate the earnings forecast score of BioCardia Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on BioCardia Inc’s future.

How do we generate the price momentum score of BioCardia Inc?

When generating the price momentum score for BioCardia Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of BioCardia Inc’s prices. A higher score indicates a more stable short-term price trend for BioCardia Inc.

How do we generate the institutional confidence score of BioCardia Inc?

To generate the institutional confidence score of BioCardia Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about BioCardia Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of BioCardia Inc.

How do we generate the risk management score of BioCardia Inc?

To assess the risk management score of BioCardia Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of BioCardia Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of BioCardia Inc.
KeyAI